CO4790179A1 - Procedimiento para la fabricacion de proteinas humanas por activacion genica endogena - Google Patents

Procedimiento para la fabricacion de proteinas humanas por activacion genica endogena

Info

Publication number
CO4790179A1
CO4790179A1 CO98042018A CO98042018A CO4790179A1 CO 4790179 A1 CO4790179 A1 CO 4790179A1 CO 98042018 A CO98042018 A CO 98042018A CO 98042018 A CO98042018 A CO 98042018A CO 4790179 A1 CO4790179 A1 CO 4790179A1
Authority
CO
Colombia
Prior art keywords
human proteins
manufacture
endogenous gene
gene activation
procedure
Prior art date
Application number
CO98042018A
Other languages
English (en)
Inventor
Michael Brandt
Reinhard Franze
Pessara Ulrich
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/113,692 external-priority patent/US6548296B1/en
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of CO4790179A1 publication Critical patent/CO4790179A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un procedimiento para la fabricación de proteínas humanaspor activación génica endógena, estando el procedimiento caracterizado por comprender: (a) seleccionar una línea celular humana por la presencia de las características siguientes: (i) un gen blanco con la secuencia de ácido nucleíco deseada, (ii) al menos 5 duplicaciones de población dentro de 14 días en un cultivo de suspensión, y (iii) al menos 5 duplicaciones de población dentro de 14 días en un medio de cultivo libre de suero, y (b) utilizar dicha línea celular que cumple las características (i) (ii) y (iii), como material de partida para la obtención de las proteínas humanas.
CO98042018A 1997-07-23 1998-07-23 Procedimiento para la fabricacion de proteinas humanas por activacion genica endogena CO4790179A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97112640 1997-07-23
EP97121073 1997-12-01
US09/113,692 US6548296B1 (en) 1997-07-23 1998-07-10 Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof

Publications (1)

Publication Number Publication Date
CO4790179A1 true CO4790179A1 (es) 1999-05-31

Family

ID=40933395

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98042018A CO4790179A1 (es) 1997-07-23 1998-07-23 Procedimiento para la fabricacion de proteinas humanas por activacion genica endogena

Country Status (6)

Country Link
US (2) US6846673B2 (es)
JP (2) JP5896960B2 (es)
KR (1) KR100622203B1 (es)
AR (1) AR016774A1 (es)
CO (1) CO4790179A1 (es)
PT (1) PT1000154E (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100622203B1 (ko) * 1997-07-23 2006-09-07 로셰 디아그노스틱스 게엠베하 내인성 유전자 활성화에 의해 사람 단백질을 생성시키는 사람 세포주를 확인하는 방법
US20050019914A1 (en) * 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
EA009326B1 (ru) * 2007-04-06 2007-12-28 Петр Генриевич ЛОХОВ Способ определения качества клеточной культуры
WO2012050175A1 (ja) 2010-10-15 2012-04-19 日本ケミカルリサーチ株式会社 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法
JP6652334B2 (ja) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
JPS62171696A (ja) 1986-01-23 1987-07-28 Sumitomo Chem Co Ltd ヒトエリスロポエチンの製造方法
US4954437A (en) 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
CA2045175C (en) * 1989-11-06 2003-03-18 Arthur I. Skoultchi Production of proteins using homologous recombination
US5328844A (en) * 1990-05-09 1994-07-12 University Of Colorado Foundation, Inc. Culture media for mammalian cells
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
WO1999005267A1 (de) * 1997-07-23 1999-02-04 Roche Diagnostics Gmbh Identifizierung humaner zellinien zur produktion humaner proteine durch endogene genaktivierung
KR100622203B1 (ko) * 1997-07-23 2006-09-07 로셰 디아그노스틱스 게엠베하 내인성 유전자 활성화에 의해 사람 단백질을 생성시키는 사람 세포주를 확인하는 방법
PT986644E (pt) * 1997-07-23 2007-01-31 Roche Diagnostics Gmbh Preparação de eritropoietina por activação genética endógena com promotores virais
US6548296B1 (en) * 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof

Also Published As

Publication number Publication date
AR016774A1 (es) 2001-08-01
JP5896960B2 (ja) 2016-03-30
KR100622203B1 (ko) 2006-09-07
US6846673B2 (en) 2005-01-25
US20020164792A1 (en) 2002-11-07
JP2013240335A (ja) 2013-12-05
KR20010022126A (ko) 2001-03-15
JP2014193187A (ja) 2014-10-09
US7214514B2 (en) 2007-05-08
US20050090007A1 (en) 2005-04-28
JP6047524B2 (ja) 2016-12-21
PT1000154E (pt) 2007-03-30

Similar Documents

Publication Publication Date Title
AR245776A1 (es) Metodo para la modificacion de las caracteristicas de expresion de un gen endogeno de un microorganismo o una linea celular determinada.
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
DK1105507T3 (da) Overekspression af önskede proteiner i eukaryote celler medieret af cyclin D1-overekspression
BR9812540A (pt) Expressão de genes endógenos por recombinaçãonão homóloga de uma construção de vetor comdna celular
AR020735A1 (es) Un procedimiento para la obtencion de un polipeptido glucosilado a partir de celulas eucarioticas
DE69512219T2 (de) Gezielte spaltung von rns mittels gezielter bindung der ribonuklease p und spaltungssequenzen
ATE87663T1 (de) Verfahren zur herstellung von faktor-viii:c-typ- proteinen.
MY125594A (en) Immortalized cell lines for virus growth
CO5601047A2 (es) Metodo de cultivo celular libre de animal
DE69920747D1 (de) Methode zur herstellung von rekombinanten zellen
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
ATE335086T1 (de) Künstliche chromosomen, die die genetische information für die bildung von rekombinantem virus enthalten
CY1105439T1 (el) Κυτταρα, μεθοδοι καλλιεργειας και η χρηση τους στη θepαπεια με αυτολογη μεταμοσχευση
EE03955B1 (et) Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks
ATE342275T1 (de) Vorübergehend-immortalisierte zellen zur verwendung in gentherapie
AR246983A1 (es) Plasmido dna recombinante, linea celular y procedimiento para producir beta-ngf humano.
EP0926237A3 (de) Nukleinsäurekonstrukte für die Gentherapie, deren Aktivität von Inhibitoren cyclinabhängiger Kinasen beeinflusst wird
CO4790179A1 (es) Procedimiento para la fabricacion de proteinas humanas por activacion genica endogena
DE69634563D1 (de) Verbesserte verfahren zur transfektion der t-zellen
DE69942564D1 (de) Methoden und zusammensetzungen für die produktion von viruspartikeln
GB2321702B (en) Methods and means relating to retrotransposon and retroviral integration
ES2109194B1 (es) Un procedimiento para producir la enzima d-aminoacido oxidasa de rhodotorula gracilis en celulas hospedantes.
DK0994955T3 (da) Öget produktion af secernerede proteiner med rekombinante gærceller
BR9909388A (pt) Uso de pelo menos uma leishmania cisteìna proteinase, vacina, proteìna cpa do l. infantum, genes cpa e cpb do l. infantum, cpa ou cpb, e, uso das proteìnas cpa e/ou cpb ou das sequências de ácido nucléico do cpa e/ou cpb
ATE318919T1 (de) Verfahren zur herstellung von proteinen in transformierten hefezellen